AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06611878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music training - minimal
Description: Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered once a month for 5 months.
Study NCT06611878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Medications, behavioural interventions and other treatments that participants may receive outside the study during the period of participation.
Study NCT06609746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thyme extract
Description: Three Gastrolit capsules daily with a low FODMAP diet for 8 weeks
Study NCT06609746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules daily with a low FODMAP diet for 8 weeks
Study NCT04647435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APSCTC
Description: APSCTC + Toragesic® placebo + Tramal® placebo
Study NCT04647435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toragesic®
Description: APSCTC placebo + Toragesic® + Tramal® placebo
Study NCT06470581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
Study NCT06470581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Patients were assigned 1:1 to a control group using only local anesthetics (Group A) and a BTX-A group (Group B). In Phase 1, the needle is inserted near the vertebrae T3 under fluoroscopic guidance. An 1 ml of non-ionized contrast medium is injected to evaluate the diffusion pattern, and 3ml of 0.75% ropivacaine is injected. After identifying a temperature increase in the ipsilateral palm within 20 min in the operating room with the prone position, 3 ml of 0.375% ropivacaine and botulinum toxin type A 75 IU mixed with 3 ml of non-preserved saline solution are injected in the patients in the control and botulinum toxin groups, respectively.
Study NCT06069362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual physiotherapy and neurodynamic exercises
Description: * Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~* Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability.
Study NCT06452550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Logistic regression (LR) prediction models
Description: Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.
Study NCT04931615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)
Description: Wound sealant
Study NCT04647435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal®
Description: APSCTC placebo + Toragesic® placebo + Tramal®
Study NCT06728033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supra-inguinal fascia iliaca compartment block
Description: Supra-inguinal fascia iliaca compartment block with 40 ml of 0.25% ropivacaine
Study NCT06728033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: intravenous tramadol at a dose of 2 mg/kg
Study NCT06727591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split Bone Block Technique
Description: An intraoral crestal incision with/out vertical arms was performed on alveolar ridge using blade no.15. After flap reflection, patroning the defect to help guide the area to be grafted from the donor site. At the chin area (donor site) unicortical cuts will be made at least 5 mm inferior to root tips, 5 mm superior to inferior border of mandible and 5 mm away from the mental foramen. The graft was luxated and split into two bone shells each 1 \~ 2 mm in thickness using disc. The bone shells and the donor site were scrapped for autogenous graft particles. Decortication of the recipient site. The graft was stabilised into the recipient site using two or more self tapping titanium screws placed midway corono-apical in the bone shell following the ridge contour. The autogenous particles were packed into the space between the split bone block and the ridge. Collagen sponge was used to cover the donor site. After 4 months the site was approached for implant placement using crestal incision
Study NCT06727916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBT-I
Description: Participants in the intervention group will receive BBT-I in 4 consecutive sessions in addition to standard care. Healthcare provider provided BBT-I to the patients.
Study NCT04931615 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no ARTISS
Description: Wound closed without sealant
Study NCT06727916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non BBT-I
Description: Patients in the control group will receive standard care.
Study NCT06728800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT 2.0
Description: FBT 2.0 is a translation of Family-Based Behavioral Treatment (FBT) into an e-health intervention product for families with a child/adolescent with obesity. FBT is an evidence-based obesity intervention that takes a family-centered approach to weight management that includes training in behavioral skills for the family, such as self-monitoring, stimulus control, problem solving, pre-planning, and impulse control. Youth with obesity, along with one participating caregiver, will be introduced to the evidence- based Traﬃc Light Eating Plan and behavioral skill training appropriate for their developmental age, while the caregiver learns positive parenting approaches to help shape and support their child's weight change efforts in addition to their own weight management goals. The ﬁnal product will consist of eight modules, each aligned with evidence-based FBT skills and competencies.
Study NCT05666973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Mesh Hernioplasty
Description: * Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture
Study NCT05666973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Mesh Hernioplasty
Description: * Steps of surgery:~  * Injection Ceftriaxone 50 mg/kg iv stat dose will be given pre-operatively~ * Incision:~* Incision given over medial 3/5 and 2.5 cms above and parallel to inguinal ligament extending from pubic tubercle upto 1 cm lateral to mid point of inguinal ligament.~  * bleeding controlled by forcep coagulation.~ * Cut the subcutaneous tissues,external oblique aponeurosis opened in layers~ * Nerve Iliohypogastric \& ilioinguinal will be preserved (by taking aside from the field)~ * Intra-operative Injection Tramadol(50 mg) and ondansetron(4 mg) iv stat dose given~ * Sac ligated with Polygalactin 2-0 suture.~ * Lichtenstein method of repair~* Mesh type: large pore polypropylene mesh~* Mesh size: 3 x 6 inches(7.5 x 15 cms)~* Mesh Fixation: polypropylene 2-0~  * External oblique closure~ * Skin closure: Ethilon 2 - 0 suture
Study NCT06728800 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information-and-referral
Description: Caregiver-youth dyads randomized to the information-and-referral control intervention will be given written educational materials. Prior to starting the intervention trial, dyads will meet for 20 minutes with a trained researcher who will provide them with educational materials used in investigators' prior studies which teaches about the impact of eating and activity behaviors on weight. Caregivers will be asked to monitor their health by using daily paper-and-pencil diaries to record eating and activity behaviors. Youth without a medical provider will be given referrals to a primary care provider in their community.
Study NCT05598567 — intervention group
Intervention type: OTHER
Intervention: target controlled infusion - total intravenous general anesthesia
Description: Both interventions are subtypes of general anesthesia.
Study NCT05598567 — intervention group
Intervention type: OTHER
Intervention: sevoflurane based balanced general anesthesia
Description: Both interventions are subtypes of general anesthesia.
Study NCT05849857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab is administered as a subcutaneous injection. The first dose is 5 mg in 0,5 mL volume, subsequent doses are 45 mg in 1,0 mL volume.
Study NCT06433947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-6602
Description: orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
Study NCT06433947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
Study NCT05859516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Every time checking pulse, evaluate the carotid artery compressibility and blood flow of peripheral arteries by ultrasound，compared with EtCO2.
Study NCT06317012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy using CAD CAM surgical guide and 3Dcustomized plate
Description: Le Fort I osteotomy will be performed with the aid of a surgical guide through the mucosal incision at the maxillary vestibule region, providing adequate surgical exposure.~The planned position will be obtained using a customized titanium plate for precise maxillary position and fixation as planned virtually on the software.
Study NCT04472702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cRFA
Description: cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
Study NCT05608057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C mesotherapy
Description: Vitamin C intra-mucosal injection; in which the site of interest will be anesthetized using a topical anesthetic agent (lidocaine gel or xylocaine gel) or infiltration anesthesia, followed by intra-mucosal field injections of 1-1.5 ml Cevarol (L-Ascorbic acid 1000 mg/5 ml
Study NCT05608057 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser
Description: Diode laser ablation: in which the site of interest will be anesthetized using infiltration anesthesia, followed by laser ablation. 980nm Diode laser will be applied using the following setting parameters: continuous mode with 980nm wavelength at 1.5 W output power.
Study NCT05470647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-4 receptor responders 1
Description: Interleukin-4 receptor was injected subcutaneously.
Study NCT05470647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-4 receptor responders 2
Description: Interleukin-4 receptor was injected subcutaneously.
Study NCT05470647 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was injected subcutaneously.
Study NCT04963790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored COVID-19 vaccine messages
Description: Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
Study NCT04963790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other health messages
Description: Other health messages unrelated to COVID-19 will be sent to participants in the control arm
Study NCT05869890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MOSES laser system
Description: A holmium laser technology widely used as the gold standard for laser lithotripsy for ureteroscopy treatment of renal calculi,
Study NCT05737511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Oral tablet of hydroxyzine 25mg at night which could be increased to TID or QID
Study NCT05737511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Oxalate
Description: The treatment as usual can include first-line, second-line and third-line recommendations
Study NCT05741333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo+ Tympanostomy Tube Device (Solo+ TTD)
Description: The Solo+ TTD is intended to deliver a tympanostomy tube through the tympanic membrane of a patient.
Study NCT04905992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline at 6%
Description: Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
Study NCT04905992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline at 6%
Description: Participants will start the sessions by inhaling a short-acting bronchodilator or an anticholinergic to avoid the presence of bronchospasm during nebulisation. The hypertonic solution (at 6%) will be administered through the Turbo Boy nebuliser (Pari®). The intervention will take place at home.
Study NCT04905992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (oscillating positive expiratory pressure therapy)
Description: Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
Study NCT04905992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance techniques (oscillating positive expiratory pressure therapy)
Description: Following nebulisation, participants will perform airway clearance techniques using an oscillating positive expiratory pressure device for at least 15 minutes. The intervention will take place at home
Study NCT05246995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI325+Sintilimab
Description: IBI325 + sintilimab combination does-escalation Patients will receive IBI325 monotherapy on Cycle 1 Day 1 ,and then receive IBI325 and sintilimab combination until progressive disease, intolerability, or other reasons leading to treatment discontinuation
Study NCT06519058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-myofascial stretching
Description: self-myofascial stretching exercise
Study NCT06519058 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy treatment, including exercises
Study NCT05473559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block with Ipack block or selective tibial nerve block
Description: Ultrasound guided
Study NCT05154877 — intervention group
Intervention type: DEVICE
Intervention: OMNI PET/CT Scan
Description: The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.
Study NCT05245552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.25ml)
Description: 7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
Study NCT05245552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine(0.5ml)
Description: 15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
Study NCT05245552 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BV)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
Study NCT05245552 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine(BY)
Description: 7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
Study NCT06359925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine
Description: After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL of\[ 5\]µg dexmedetomidine. The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
Study NCT06359925 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suprazygomatic maxillary nerve block using Bupivacaine
Description: After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL normal saline . The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
Study NCT04683068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message comparison
Description: Message comparison
Study NCT04683068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Message comparison
Description: Message comparison